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Background: Eosinophilic otitis media (EOM) is an intractable disease characterized by a remarkably
viscous effusion and accumulation of numerous eosinophils in both the middle ear effusion and the
mucosa. The key factors in EOM pathogenesis remain unclear. The purpose of this study is to identify the
important factors involved in EOM pathogenesis.
Methods: Middle ear effusion samples were collected from 12 patients with EOM and 9 patients with
secretory otitis media (SOM), as controls. Multiple cytokines in the effusion were measured using a Bio-
Plex™ Human Cytokine 27-Plex panel. Eosinophil-derived neurotoxin (EDN) and elastase were measured
by ELISA. The concentrations of EDN, elastase, and each cytokine were compared between the EOM and
SOM groups. Furthermore, in the EOM group, each cytokine was examined for correlation with EDN and
elastase.
Results: EDN and elastase concentrations were signiﬁcantly higher in the EOM group than in the SOM
group (p < 0.05). IL-5, IL-1b, MIP-1a, G-CSF, IL-1ra, IL-4, IFN-g, MIP-1b, IL-10, TNF-a, VEGF, and IL-2
concentration was signiﬁcantly higher in the EOM group than in the SOM group (p < 0.05). Signiﬁcant
positive correlations were found between EDN and IL-1ra, IL-2, IL-5, IL-9, IL-13, eotaxin, MIP-1a, PDGF-
BB, and RANTES in the EOM group (p < 0.05).
Conclusions: Our study showed that IL-5, IL-2, MIP-1a, and IL-1ra are the important factors involved in
EOM pathogenesis. Furthermore, not only eosinophil, but also neutrophil are involved in middle ear
inﬂammation of EOM.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.yngology, The Jikei University
u, Tokyo 105-8461, Japan.
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Eosinophilic otitis media (EOM) is an intractable disease
characterized by a remarkably viscous effusion and accumulation
of numerous eosinophils in both the middle ear effusion and the
mucosa. EOM is associated with adult-onset bronchial asthma,
whether atopic or non-atopic, and chronic rhinosinusitis (CRS)
with nasal polyps showing accumulation of numerousevier B.V. All rights reserved.
H. Uchimizu et al. / Allergology International 64 (2015) S18eS23 S19eosinophils. Other EOM clinical characteristics are (1) bilateral
otitis media, (2) resistance to conservative treatments other than
steroids, and (3) no association with type I allergy. In EOM, the
chronic, primarily eosinophilic, inﬂammation is thought to occur
in the middle ear mucosa, which is an extension of the respira-
tory tract mucosa.1 Furthermore, at the hearing level, EOM may
cause the deterioration of the bone-conduction hearing level2,3
and, occasionally, leads to deafness that requires cochlear
implantation.4
CRS with nasal polyps is characterized by a type 2 helper T cell
(Th2) cytokine proﬁle. It is thought that interleukin 5 (IL-5) and
eotaxin are the most important factors causing eosinophil accu-
mulation in nasal polyps.5e8 Therefore, EOM is thought to present a
cytokine proﬁle similar to that of CRS with nasal polyps. Some
studies have been designed to determine the relationship between
EOM and eosinophil-active cytokines.9,10 These studies reported
the presence of IL-5 and eotaxin in the middle ear effusion. How-
ever, only few cytokines were examined. Thus, which cytokines
and/or chemokines are the most important factors in EOM patho-
genesis remains unclear.
In this study, we found that IL-5, IL-2, macrophage inﬂammatory
protein-1a (MIP-1a), and IL-1 receptor antagonist (IL-1ra) were
important factors involved in EOM pathogenesis. These cytokines
may have potential as therapeutic targets for EOM treatment such
as anti-IL-5 antibody therapy.Methods
Patients
All patients were treated at the Department of Otorhinolaryn-
gology of The Jikei University Hospital. Middle ear effusion samples
were collected from patients who had given written informed
consent for participation in the study. The study was conducted in
accordance with the ethical standards of Jikei University. EOM
diagnosis was based upon the following criteria proposed by Nag-
amine et al.9: (1) presence of yellow and extremely viscous middle
ear effusion containing predominantly eosinophils and (2) prece-
dence and association with adult bronchial asthma (atopic or non-
atopic). In this study, middle ear effusion samples were obtained
from 12 patients with EOM who met the above diagnostic criteria.
In addition, like EOM, adult secretory otitis media (SOM) is a
chronic inﬂammatory disease that shows accumulation of an
effusion in the middle ear without any accompanying bacterial
infection or acute inﬂammation. In the early stage of EOM onset,
the ﬁndings can be very similar to SOM. For this reason, SOM is a
disease that is very difﬁcult to distinguish from EOM. Accordingly,
middle ear effusion samples were obtained from nine patients with
adult SOM without bronchial asthma or chronic rhinosinusitis as
controls.
Patients who were diagnosed as having asthma by an internal
medicine specialist in the respiratory organs and were adminis-
tered drugs for asthma were designated as having asthma. A
diagnosis of aspirin-intolerant asthma was made from an episode
of the onset of asthma attack after using non-steroidal anti-in-
ﬂammatory drugs. A diagnosis of CRS with nasal polyps was made
on the basis of an endoscopic examination and a CT scan. In addi-
tion, allergen-speciﬁc IgE antibodies for ﬁve inhalant allergens
(house dust, mites, cedar pollen, Alternaria alternate, and Aspergillus
fumigatus) were measured by using CAP-RAST and allergen-speciﬁc
IgE values of 0.7UA/mL or higher were considered positive. Atopy
was deﬁned as a positive response to at least one of these ﬁve
allergens.Collection of middle ear effusion samples
According to the tympanic membrane ﬁndings, EOM is classiﬁed
into two types. The chronic otitis media type with tympanic
membrane perforation and SOM typewithout tympanic membrane
perforation. Middle ear effusion samples were collected from pa-
tients with EOM through the tympanic membrane perforation us-
ing a Jun-Tym-Tap® middle ear ﬂuid aspirator/collector (Medtronic
Xomed, Jacksonville, FL, USA) or after myringotomy via the external
ear canal. Middle ear effusion samples were collected from patients
with SOM after myringotomy. After dilution with an equal volume
of saline and vortexing, effusion samples were stored below20 C
until used.
Measurement of cytokine, END, and elastase
After thawing at room temperature, effusion samples were
diluted 1:10 with 0.5% human serum albumin in phosphate-
buffered saline. After thorough vortexing, the effusion samples
were centrifuged at 2500 rpm for 5 min at 4 C. The supernatants
were assayed for multiple cytokines using the Bio-Plex™ Human
Cytokine 27-Plex panel (Bio-Rad Laboratories, Hercules, CA, USA)
according to the manufacturer's instructions. The panel includes
the following cytokines: IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, basic ﬁbroblastic
growth factor (bFGF), granulocyte-colony stimulating factor (G-
CSF), granulocyte macrophage-colony stimulating factor (GM-CSF),
interferon g (IFN-g), interferon-inducible protein-10 (IP-10),
monocyte chemoattractant protein-1 (MCP-1), MIP-1a, MIP-1b,
platelet-derived growth factor-BB (PDGF-BB), regulated upon acti-
vation, normal T expressed and secreted (RANTES), tumor necrosis
factor a (TNF-a), and vascular endothelial growth factor (VEGF). As
respective indicators of eosinophil and neutrophil activation,
eosinophil-derived neurotoxin (EDN) and neutrophil elastase were
measured with an EDN enzyme-linked immunosorbent assay
(ELISA; MBL, Nagoya, Japan) and human PMN elastase ELISA
(Bender MedSystems, Vienna, Austria), respectively, according to
the manufacturers' recommendations. The concentrations of EDN,
elastase, and each cytokine in the effusionwere compared between
the EOM and SOM groups. Furthermore, each cytokine was exam-
ined for possible correlation with EDN and elastase in the EOM
group.
Statistical analysis
All statistical analyses were performed using the statistical
software SPSS version 16 (IBM SPSS Japan Inc., Tokyo, Japan). The
EOM and SOM groups were compared by ManneWhitney's U-test.
Correlations between variables were analyzed using Spearman's
correlation coefﬁcient by rank test. Differences with a p-value of
less than 0.05 were considered statistically signiﬁcant.
Results
Patient background characteristics in the EOM and SOM groups
Table 1 presents the data on the patient background charac-
teristics in both the EOM and SOM groups. The groups showed no
signiﬁcant differences with regard to the number of patients, age,
or gender. The peripheral eosinophil count and percentage were
signiﬁcantly higher in the EOM group than in the SOM group
(p < 0.01), but the total serum IgE level showed no signiﬁcant
difference between the groups. In the EOM group, nine patients
presented the chronic otitis media type with tympanic mem-
Table 1
Patient background characteristics in the EOM and SOM groups.
EOM SOM
Patients (n) 12 9
Age (years) 51.1 ± 11.0 54.7 ± 12.3
Male/Female 7/5 5/4
Peripheral eosinophils
Count, /mL 1051.8 ± 1302.6y 183.5 ± 150.6
Percentage 13.4 ± 13.1y 2.6 ± 1.4
Total serum IgE, IU/mL 813.4 ± 1266.7 265.3 ± 108.1
Atopy 8/12 3/9
Bronchial asthma 12/12 0/9
Aspirin-intolerant asthma 1/12 0/9
CRS with nasal polyps 12/12 0/9
Tympanic membrane perforation 9/12 0/9
Steroid therapy
Topical eardrops 6/12 0/9
Systemic 0/0 0/9
Data are expressed as mean ± standard deviation.
EOM, eosinophilic otitis media; SOM, secretory otitis media; CRS, chronic
rhinosinusitis.
y Signiﬁcant difference between the EOM and SOM groups (p < 0.01).
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treated with topical steroid eardrops, but nobody had been
treated with systemic steroid therapy. On the other hand, nobody
had been treated with either topical or systemic steroid therapy
in the SOM group.
Comparison of end and elastase concentrations between the EOM
and SOM groups
EDN and elastase concentrations in the effusion were
compared between the EOM and SOM groups (Fig. 1). EDN con-
centration was signiﬁcantly higher in the EOM group than in the
SOM group (p < 0.001). Furthermore, elastase concentration was
signiﬁcantly higher in the EOM group than in the SOM group
(p < 0.05).
Comparison of cytokine concentrations between the EOM and SOM
groups
Each cytokine concentration in the effusion was compared be-
tween the EOM and SOM groups (Fig. 2). The concentration of IL-5,
IL-1b, MIP-1a, G-CSF, IL-1ra, IL-4, IFN-g, MIP-1b, IL-10, TNF-a, VEGF,
and IL-2 (in descending order of p-value) was signiﬁcantly higher in
the EOM group than in the SOM group (p < 0.05). However, thereFig. 1. Comparison of EDN and elastase concentrations between the EOM and SOM
groups. *p < 0.001, **p < 0.05. EDN, eosinophil-derived neurotoxin.was no statistical signiﬁcant difference in eotaxin or RANTES con-
centrations between the EOM and SOM groups. On the other hand,
IP-10 concentrationwas signiﬁcantly higher in the SOM group than
in the EOM group (p < 0.01).
Histopathological ﬁnding of middle ear effusion from patient with
EOM
The histopathological ﬁnding of middle ear effusion from pa-
tient with EOM is shown in Fig. 3. Numerous inﬂammatory cells
inﬁltrated in the middle ear effusion. Not only numerous eosino-
phils (black arrows), but also numerous neutrophils (white arrows)
were observed.
Correlations between EDN and each cytokine in the EOM group
Signiﬁcant positive correlations were found between EDN and
IL-1ra, IL-2, IL-5, IL-9, IL-13, eotaxin, MIP-1a, PDGF-BB, and RANTES
in the EOM group (p < 0.05) (Table 2).
Correlations between elastase and each cytokine in the EOM group
Signiﬁcant positive correlations were found between elastase
and IL-6 and PDGF-BB in the EOM group (p < 0.05), while a negative
correlation was found with TNF-a (p < 0.05) (Table 2).
Discussion
Previous EOM studies examined only a few cytokines such as
IL-5, eotaxin, and RANTES.9,10 This is the ﬁrst report to show the
simultaneous assay of multiple cytokines and comparison with
not only an indicator of eosinophil activation such as EDN, but also
an indicator of neutrophil activation such as neutrophil elastase. In
this study, IL-5, IL-2, MIP-1a, and IL-1ra concentration was
signiﬁcantly different between the EOM and SOM groups and
correlated with EDN in the EOM group (Fig. 4). This result suggests
that these four cytokines are speciﬁcally involved in EOM
pathogenesis.
CRS with nasal polyps is characterized by intense eosinophilic
inﬂammation and high IL-5 levels in the nasal tissue. Therefore, IL-
5 is an important factor for eosinophil accumulation and activa-
tion in CRS with nasal polyps.5e7 Furthermore, IL-5 is a key factor
not only in CRS with nasal polyps, but also in several eosinophil-
associated disorders. Clinical trials of anti-IL-5 antibody therapy
have been performed for these disorders.11e13 Similar to these
eosinophil-associated disorders, our results also suggest that IL-5
is an important factor for eosinophil accumulation in the middle
ear in EOM. This result is in agreement with that of a previous
study,10 which reported that the concentration of eosinophil
cationic proteinwas positively correlated with that of IL-5 and that
IL-5 may play an important role in the recruitment of eosinophils
in the middle ear. On the other hand, it is interesting that not only
IL-5, which is a Th2 cytokine, but also IL-2, which is a Th1 cytokine,
is also involved in EOM pathogenesis. In addition, IFN-g concen-
tration in the EOM group was also signiﬁcantly higher than in the
SOM group. Thus, the cytokine proﬁle in the effusion from patients
with EOM included both Th2 and Th1 cytokines. It has generally
been thought that eosinophilic inﬂammation is associated with
Th2 immune responses and that nasal polyps are characterized by
a Th2 cytokine proﬁle. However, several studies reported that the
cytokine pattern in nasal polyps is not Th2 cytokine-predominant,
but a mixed type, including upregulation of both Th2 and Th1.14e16
Similarly, our results suggest that both Th2 and Th1 cytokines are
also important factors in EOM pathogenesis.
Fig. 2. Comparison of cytokines concentrations between the EOM and SOM groups *p < 0.05, **p < 0.01, ***p < 0.001. IL, interleukin; bFGF, basic ﬁbroblastic growth factor; G-CSF,
granulocyte-colony stimulating factor; GM-CSF, granulocyte macrophage-colony stimulating factor; IFN-g, interferon g, IP-10, interferon-inducible protein-10; MCP, monocyte
chemoattractant protein; MIP, macrophage inﬂammatory protein; PDGF-BB, platelet-derived growth factor-BB; RANTES, regulated upon activation, normal T expressed and
secreted, TNF-a, tumor necrosis factor a; VEGF, vascular endothelial growth factor.
H. Uchimizu et al. / Allergology International 64 (2015) S18eS23 S21MIP-1a is a chemokine that binds to CeC chemokine receptor-1,
which is expressed on neutrophils, eosinophils, monocytes, T
lymphocytes, and basophils, with high afﬁnity. It is conﬁrmed that
MIP-1a was increased in the bronchoalveolar lavage (BAL) ﬂuidfrom bronchial asthma after an allergen challenge.17 MIP-1a also
induces eosinophil migration and, like RANTES, MIP-1a is an
important mediator of the inﬂammatory process in which eosino-
phil predominate.18 Furthermore, MIP-1a and RANTES are major
Fig. 3. Histopathological ﬁnding of the middle ear effusion from patient with EOM
(Hematoxylin and Eosin staining,  400). Numerous eosinophils (black arrows) and
neutrophils (white arrows) are observed.
H. Uchimizu et al. / Allergology International 64 (2015) S18eS23S22chemotactic proteins involved in eosinophil accumulation during
allergy airway responses.19 Our results indicate that MIP-1a is a
more important factor involved in eosinophil accumulation in EOM
than RANTES.
IL-1ra is an anti-inﬂammatory cytokine that blocks the action of
IL-1a and IL-1b functional ligands by competitive inhibition at the
IL-1 receptor level.20 Therefore, when IL-1ra is producedTable 2
Correlation between each cytokine and EDN or elastase in the EOM group.
EDN Elastase
r p Value r p Value
IL-1b 0.124 0.717 0.450 0.163
IL-1ra 0.725 0.008 0.087 0.789
IL-2 0.755 0.007 0.044 0.897
IL-4 0.185 0.584 0.230 0.495
IL-5 0.654 0.021 0.085 0.792
IL-6 0.507 0.092 0.648 0.023
IL-7 0.401 0.196 0.269 0.398
IL-8 0.137 0.672 0.030 0.926
IL-9 0.658 0.028 0.018 0.958
IL-10 0.033 0.924 0.097 0.777
IL-12 0.376 0.254 0.397 0.227
IL-13 0.769 0.006 0.163 0.632
IL-15 0.495 0.102 0.231 0.471
IL-17 0.544 0.068 0.371 0.236
Eotaxin 0.755 0.005 0.131 0.684
bFGF 0.278 0.381 0.137 0.670
G-CSF 0.149 0.661 0.146 0.668
GM-CSF 0.395 0.204 0.248 0.437
IFN-g 0.311 0.325 0.230 0.472
IP-10 0.508 0.110 0.560 0.073
MCP-1 0.026 0.939 0.087 0.800
MIP-1a 0.739 0.009 0.003 0.992
MIP-1b 0.241 0.475 0.247 0.463
PDGF-BB 0.733 0.007 0.661 0.019
RANTES 0.822 0.001 0.277 0.387
TNF-a 0.382 0.220 0.674 0.016
VEGF 0.011 0.973 0.085 0.792
r, correlation coefﬁcient; IL, interleukin; bFGF, basic ﬁbroblastic growth factor; G-
CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte macrophage-
colony stimulating factor; IFN-g, interferon g; IP-10, interferon-inducible protein-
10; MCP, monocyte chemoattractant protein; MIP, macrophage inﬂammatory pro-
tein; PDGF-BB, platelet-derived growth factor-BB; RANTES, regulated upon activa-
tion, normal T expressed and secreted; TNF-a, tumor necrosis factor a; VEGF,
vascular endothelial growth factor; EDN, eosinophil derived neurotoxin.excessively compared to IL-1, IL-1 activity is controlled and, as a
result, the inﬂammatory reaction may be suppressed. Our results
indicate that IL-1ra is one of the important factors involved in EOM
pathogenesis. Compared to patients with adult respiratory distress
syndrome, patients with acute eosinophilic pneumonia had high IL-
1ra BAL ﬂuid levels, which decreased after the resolution of the
symptoms and completion of a course of corticosteroids.21
Furthermore, IL-1 induced eosinophil accumulation in the skin.
This eosinophil accumulation was blocked by IL-1ra.22 In EOM, IL-
1ra may play an important role in suppressing the eosinophilic
inﬂammation in the middle ear.
In our study, both EDN and elastase concentrations were
signiﬁcantly higher in the EOM group than in the SOM group.
These results indicate that not only eosinophils, but also neu-
trophils were recruited at the same time in EOM. Actually, both
numerous eosinophils and neutrophils were observed in the
middle ear effusion from patient with EOM, histopathologically.
This ﬁnding indicates that both eosinophils and neutrophils are
likely involved in the EOM middle ear inﬂammation. In the clinic,
when EOM symptoms worsen such as an increase of the viscous
effusion, we sometimes see a response not only to steroids, but
also to antibiotic eardrops. This ﬁnding on the concentration of
elastase supports our above-noted clinical experience. We sur-
mise that an additional bacterial infection might be a factor
aggravating the middle ear inﬂammation in EOM. However, the
nine patients that had a tympanic membrane perforation among
the 12 patients with EOM may be easily infected with bacteria via
the external ear canal compared to the patients without tympanic
membrane perforation. Therefore, further comparative studies
will be needed in patients with EOM without tympanic mem-
brane perforation.
Only the concentration of IP-10, which is a cytokine that is
expressed in response to infection by various viruses,23,24 was
signiﬁcantly higher in the SOM group than in the EOM group.
Recently, we have reported that serum IP-10 was elevated in acute
exacerbation of childhood asthma infected by rhinovirus and res-
piratory syncytial virus.25 Like asthma, pediatric otitis media is
known to be associated with viral upper respiratory tract infec-
tion.26 On the other hand, the pathogenesis of adult SOM is not yet
well understood and relationship between adult SOM and viral
infection has not been pointed out. Therefore, our ﬁnding suggests
that viral upper respiratory tract infections may be involved in the
pathogenesis of adult SOM.
In the year 2011, Iino et al. reported the new diagnostic criteria
for EOM. So far, there were no established diagnostic criteria for
EOM.27 When this study started, these new diagnostic criteria
were not established yet. Therefore, in this study, we used the
criteria proposed by Nagamine et al.,9 which focus on typical
patients with EOM. However, not all patients with EOM have
bronchial asthma or eosinophilic rhinosinusitis. In the new
diagnostic criteria, the presence of eosinophil-dominant effusion
is the major criterion. On the other hand, highly viscous middle
ear effusion, resistance to conventional treatments for otitis
media, association with bronchial asthma, and association of
nasal polyposis are minor criteria. A patient with a major item
and, at least, two minor items is diagnosed with EOM. Even if
these new diagnostic criteria were used, all patients recruited in
our study would be diagnosed with EOM and we support these
new diagnostic criteria for EOM.
In conclusion, our study showed that IL-5, IL-2, MIP-1a, and IL-
1ra are speciﬁcally involved in EOM pathogenesis of. These cyto-
kines may have potential as therapeutic targets for EOM such as
anti-IL-5 antibody therapy. Not only anti-IL-5 antibody, but IL-1ra
has also been tested in clinical trials for several disorders.28e30
Therefore, these may also be effective for EOM treatment.
Fig. 4. Possible important factors involved in the pathogenesis of EOM. IL, interleukin; G-CSF, granulocyte-colony stimulating factor; IFN-g, interferon g; IP-10, interferon-inducible
protein-10; MIP, macrophage inﬂammatory protein; PDGF-BB, platelet-derived growth factor-BB; RANTES, regulated upon activation, normal T expressed and secreted; TNF-a,
tumor necrosis factor a; VEGF, vascular endothelial growth factor; EDN, eosinophil-derived neurotoxin.
H. Uchimizu et al. / Allergology International 64 (2015) S18eS23 S23However, most studies on EOM are still at the early stages and
much further investigation is necessary. In the near future, EOM
pathogenesis should be sufﬁciently clariﬁed to allow the develop-
ment of the therapeutic tools needed by physicians to prevent
deafness due to EOM.
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